Neurocrine Biosciences Inc. (NBIX) Fell After Phase 2 Study Failed

Neurocrine Biosciences Inc. (NBIX) announced after the bell Tuesday that its Phase II Tourette syndrome T-Force GREEN study of INGREZZA did not meet its primary endpoint.

from RTT - Before the Bell http://ift.tt/2rUbaJJ
via IFTTT